Supervised Pretraining through Contrastive Categorical Positive Samplings to Improve COVID-19 Mortality Prediction

The Role and Applications of Artificial Intelligence in the Treatment of Chronic Pain

PURPOSE OF REVIEW

This review aims to explore the interface between artificial intelligence (AI) and chronic pain, seeking to identify areas of focus for enhancing current treatments and yielding novel therapies.

RECENT FINDINGS

In the United States, the prevalence of chronic pain is estimated to be upwards of 40%. Its impact extends to increased healthcare costs, reduced economic productivity, and strain on healthcare resources. Addressing this condition is particularly challenging due to its complexity and the significant variability in how patients respond to treatment. Current options often struggle to provide long-term relief, with their benefits rarely outweighing the risks, such as dependency or other side effects. Currently, AI has impacted four key areas of chronic pain treatment and research: (1) predicting outcomes based on clinical information; (2) extracting features from text, specifically clinical notes; (3) modeling 'omic data to identify meaningful patient subgroups with potential for personalized treatments and improved understanding of disease processes; and (4) disentangling complex neuronal signals responsible for pain, which current therapies attempt to modulate. As AI advances, leveraging state-of-the-art architectures will be essential for improving chronic pain treatment. Current efforts aim to extract meaningful representations from complex data, paving the way for personalized medicine. The identification of unique patient subgroups should reveal targets for tailored chronic pain treatments. Moreover, enhancing current treatment approaches is achievable by gaining a more profound understanding of patient physiology and responses. This can be realized by leveraging AI on the increasing volume of data linked to chronic pain.

Artificial intelligence-driven prediction of COVID-19-related hospitalization and death: a systematic review

Aim

To perform a systematic review on the use of Artificial Intelligence (AI) techniques for predicting COVID-19 hospitalization and mortality using primary and secondary data sources.

Study eligibility criteria

Cohort, clinical trials, meta-analyses, and observational studies investigating COVID-19 hospitalization or mortality using artificial intelligence techniques were eligible. Articles without a full text available in the English language were excluded.

Data sources

Articles recorded in Ovid MEDLINE from 01/01/2019 to 22/08/2022 were screened.

Data extraction

We extracted information on data sources, AI models, and epidemiological aspects of retrieved studies.

Bias assessment

A bias assessment of AI models was done using PROBAST.

Participants

Patients tested positive for COVID-19.

Results

We included 39 studies related to AI-based prediction of hospitalization and death related to COVID-19. The articles were published in the period 2019-2022, and mostly used Random Forest as the model with the best performance. AI models were trained using cohorts of individuals sampled from populations of European and non-European countries, mostly with cohort sample size <5,000. Data collection generally included information on demographics, clinical records, laboratory results, and pharmacological treatments (i.e., high-dimensional datasets). In most studies, the models were internally validated with cross-validation, but the majority of studies lacked external validation and calibration. Covariates were not prioritized using ensemble approaches in most of the studies, however, models still showed moderately good performances with Area under the Receiver operating characteristic Curve (AUC) values >0.7. According to the assessment with PROBAST, all models had a high risk of bias and/or concern regarding applicability.

Conclusions

A broad range of AI techniques have been used to predict COVID-19 hospitalization and mortality. The studies reported good prediction performance of AI models, however, high risk of bias and/or concern regarding applicability were detected.

Multi-scale Multi-structure Siamese Network (MMSNet) for Primary Open-Angle Glaucoma Prediction

Primary open-angle glaucoma (POAG) is one of the leading causes of irreversible blindness in the United States and worldwide. POAG prediction before onset plays an important role in early treatment. Although deep learning methods have been proposed to predict POAG, these methods mainly focus on current status prediction. In addition, all these methods used a single image as input. On the other hand, glaucoma specialists determine a glaucomatous eye by comparing the follow-up optic nerve image with the baseline along with supplementary clinical data. To simulate this process, we proposed a Multi-scale Multi-structure Siamese Network (MMSNet) to predict future POAG event from fundus photographs. The MMSNet consists of two side-outputs for deep supervision and 2D blocks to utilize two-dimensional features to assist classification. The MMSNet network was trained and evaluated on a large dataset: 37,339 fundus photographs from 1,636 Ocular Hypertension Treatment Study (OHTS) participants. Extensive experiments show that MMSNet outperforms the state-of-the-art on two "POAG prediction before onset" tasks. Our AUC are 0.9312 and 0.9507, which are 0.2204 and 0.1490 higher than the state-of-the-art, respectively. In addition, an ablation study is performed to check the contribution of different components. These results highlight the potential of deep learning to assist and enhance the prediction of future POAG event. The proposed network will be publicly available on https://github.com/bionlplab/MMSNet.

Automated diagnosing primary open-angle glaucoma from fundus image by simulating human's grading with deep learning

Primary open-angle glaucoma (POAG) is a leading cause of irreversible blindness worldwide. Although deep learning methods have been proposed to diagnose POAG, it remains challenging to develop a robust and explainable algorithm to automatically facilitate the downstream diagnostic tasks. In this study, we present an automated classification algorithm, GlaucomaNet, to identify POAG using variable fundus photographs from different populations and settings. GlaucomaNet consists of two convolutional neural networks to simulate the human grading process: learning the discriminative features and fusing the features for grading. We evaluated GlaucomaNet on two datasets: Ocular Hypertension Treatment Study (OHTS) participants and the Large-scale Attention-based Glaucoma (LAG) dataset. GlaucomaNet achieved the highest AUC of 0.904 and 0.997 for POAG diagnosis on OHTS and LAG datasets. An ensemble of network architectures further improved diagnostic accuracy. By simulating the human grading process, GlaucomaNet demonstrated high accuracy with increased transparency in POAG diagnosis (comprehensiveness scores of 97% and 36%). These methods also address two well-known challenges in the field: the need for increased image data diversity and relying heavily on perimetry for POAG diagnosis. These results highlight the potential of deep learning to assist and enhance clinical POAG diagnosis. GlaucomaNet is publicly available on https://github.com/bionlplab/GlaucomaNet .